



Vaccines and Global Health: The Week in Review
14 June 2025 :: Issue 803
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Gavi

Global Summit: Health & Prosperity through Immunisation

Brussels, Belgium | 25 June 2025

Gavi's high-level pledging summit, to be co-hosted by the European Union and the Gates Foundation, seeks to raise at least US\$ 9 billion from our donors to fund our ambitious strategy to protect 500 million children, saving at least 8 million lives from 2026–2030, protect our world from the threat of pandemics, and protect communities from conflict, climate change and other global challenges.

Gavi's most ambitious strategic period ever

A successful replenishment for Gavi will enable the Vaccine Alliance to implement its most impactful strategic period ever. Outcomes, as set out in Gavi's Investment Opportunity, are expected to include: immunising at least 500 million children; saving an additional 8–9 million lives; generating at least US\$ 100 billion in economic benefits for Gavi implementing countries; unprecedented levels of co-financing, with implementing countries contributing US\$ 4 billion towards the cost of immunisation programmes; and boosting global health security by responding to 150 disease outbreaks...

Gavi's Investment Opportunity - 2026–2030

Investing in Gavi's next strategic cycle gives donors a unique opportunity to help to improve the health of people in the world's lowest-income countries, strengthening global health security in turn.

.....

The Gavi Leap: radical transformation for a new global health architecture

Comment

Sania Nishtar snishtar@gavi.org

The Lancet, Online first June 04, 2025

It has long been acknowledged that the global health system needs reform. Although this system has improved public health, saved lives, and advanced health equity,^{1,2} it remains fragmented, uncoordinated, at times inefficient, and in some settings even a barrier to progress.³ **Now, in the harsh light of geopolitical realities in 2025 and an unprecedented squeeze on funding from traditional donor countries,⁴ discussions about how to reform global health have taken on an existential quality.**

As the Chief Executive Officer of Gavi, the Vaccine Alliance, I believe that transformative change is required to protect the gains of the past and to secure further progress in the future. **The global health system needs to embrace a new reality in which international institutions have a clear understanding of their mandates and their lifespans and work seamlessly together to serve the interests of the countries that request their support.** This will require difficult conversations and some tough choices about the form, function, and, in some cases, the continuity of some institutions going forward as we seek to deliver the maximum public health benefits for the funding available.

Gavi, a public–private partnership, can point to a quantifiable impact on health and development over the past 25 years. We have helped to vaccinate more than 1·1 billion children in low-income and

middle-income countries and prevented more than 18 million deaths from vaccine-preventable diseases.¹ But this record does not make us an exception to the challenges or the criticisms facing the global health architecture.³

When I joined Gavi just over a year ago, I began a radical transformation of the organisation to embrace new ways of working that would prepare us to deliver the goals of our **next 5-year strategic period (2026–30), known as Gavi 6.0.**⁵ **At the centre of the Gavi Leap, as we call this process of transformation, are four principles** that I believe have broader relevance for our global health peers and partners as we seek to remake the global health landscape, and restore confidence and optimism in the ability of global health institutions to reshape the world for the better.

Country-centricity is the first organising principle of the Gavi Leap. Currently, already under-resourced countries cope with cumbersome parallel processes and reporting indicators of different global health agencies with agendas that are not aligned. In alignment with the 2023 Lusaka Agreement on the Future of Global Health Initiatives process,⁶ Gavi has taken concrete steps to reform our processes to ensure they are responsive to country needs, not burdensome. **From 2026 onwards, countries will have much more agency** over how Gavi support for vaccine programmes and the health systems that deliver them is deployed. Gavi is in the process of simplifying and streamlining engagement with countries through a root and branch reform of our grant-making process.

From eight grant opportunities, or windows, for Gavi-eligible countries to apply for support that each followed a different timetable, **Gavi is moving to one grant window for the Gavi 6.0 strategic cycle.** This means that countries will only need to apply for funding once during the Gavi 6.0 period, and all of that funding will be aligned with the priorities set out in Gavi's 6.0 strategy,⁵ which was itself developed in close consultation with countries to ensure it reflected national priorities. **A new monitoring strategy will link metrics with accountability for all partners in our vaccine alliance—starting with the Secretariat—for better delivery and coherence.**

These changes, along with a further evolution of the way we operate at the country level during the Gavi 6.0 period, also offer an unprecedented partnership opportunity for global health initiatives, including the **Global Fund to Fight AIDS, Tuberculosis and Malaria, to align grant cycles and metrics, programme jointly, and establish a mandated model of health systems collaboration.** We are already working together to realise this potential. In addition, Gavi is supporting the aspiration of countries in Africa to expand their own vaccine manufacturing capacity.⁷ Putting countries at the centre of global health, rather than prioritising the agendas of institutions in the Global North, is an overdue rebalancing of agency that can improve efficiency and accelerate impact.

The second principle of the Gavi Leap is self-reliance. Global health institutions can only be truly country-centric if they are designed to empower and enable countries to assume full responsibility for health programmes. Gavi's model of financial support has always been predicated on the principle that countries pay more towards the cost of immunisation as their national income rises, until they reach a threshold at which they transition to full self-financing.

This model works, as is evidenced by 19 countries graduating from Gavi support. Almost all countries that are eligible for Gavi support meet the full co-financing costs of their immunisation programmes.¹ Crucially, this model also has strong support from national governments, as evidenced by the Abidjan Declaration, in which nine African countries agreed to concrete steps towards vaccine self-reliance.⁸ That is why Gavi is supporting countries to unlock more resources for immunisation, including through support for budget planning and public finance management, and by facilitating partnerships with multilateral development banks to support transitions to vaccine self-reliance.⁹ **Gavi believes**

cultivating support for self-reliance should be a guiding principle of all global health organisations.

Focused mandates for global health institutions is the third principle. Fragmentation and duplication of efforts are inevitable and often inadvertent consequences of mission creep as global health organisations evolve in response to crises, donor priorities, and competition.³ Over the next 5 years, **Gavi will work with renewed focus on our core strengths of market shaping and innovative finance** to save lives and strengthen global health security by improving access to vaccines. Gavi has succeeded as a vaccine alliance because we leverage the comparative advantage of each of our public and private partners, from the technical expertise and the procurement power of UN agencies to the agility of manufacturers and the community knowledge of civil society. A similar focus on defined and discrete mandates for organisations working towards shared, country-driven goals within global health would enable the system to achieve more for less.

The fourth principle is finite lifespans for operational global health entities. A flaw in the current global health architecture is that few institutions have sunset clauses with an end date for the organisation written into their articles of incorporation. This includes Gavi, and although it is our goal to put ourselves out of business, there is no timetable for doing so. Having clear parameters for the termination of operational duties provides focus and urgency, and a clear incentive to help countries achieve self-reliance. This will be an important theme in Gavi's work on the future of immunisation.

The world around us forces us to confront the profound challenges facing global health with speed, concrete actions, and ambition. **The four principles of the Gavi Leap could serve as a blueprint for a wider global health leap to improve the health and the lives of those most in need during this period of unprecedented change.** We stand ready to work with all stakeholders to make that happen. **And to that end, we will propose a process** that, we hope, can bring us together to forge a new consensus on the future of our global health architecture.

Competing Interests

I am the Chief Executive Officer of Gavi, the Vaccine Alliance and declare no other competing interests.

.....

Statement on the first joint GPEI-Gavi Board Meeting

13 June 2025

On 19 June 2025, the Boards of the Global Polio Eradication Initiative (GPEI) and Gavi, the Vaccine Alliance **will convene to discuss their shared priorities:** delivering a polio-free world, building stronger immunization and health systems to protect all children from vaccine-preventable diseases and strengthening our collective health security.

Led by Board Chairs Professor José Manuel Barroso (Chair, Gavi Board) and Dr. Chris Elias (Chair, Polio Oversight Board of GPEI), the meeting will aim to deepen the understanding of each other's priorities, approaches and timelines; prioritize opportunities for enhanced collaboration, especially in the world's most fragile settings; and, ultimately, agree to develop an integrated plan of action with clear goals, deliverables and monitoring frameworks that will advance the joint priority of reaching all children with life-saving vaccines.

Representatives from key donor and implementing countries, civil society organizations, Rotary International, the US Centers for Disease Control (CDC), UNICEF, World Health Organization (WHO), and the Gates Foundation will also be in attendance...

.....

::::::

US HHS/FDA/CDC/ – Vaccines/Immunization Policy Actions/Regulatory Performance

Editor's Note

As we have observed in previous editions, the gravity and velocity of U.S. government actions impacting vaccines and immunization is extraordinary and, in too many instances, deeply troubling.

We have noted our intention to complement official announcements by HHS/FDA/CDC and other government agencies by selectively including comment and analysis appearing in the media and through organizational announcements. This additional content is intended to provide a more comprehensive, but not exhaustive, record.

In a series of unprecedented and distressing actions this week, HHS announced the removal/retirement of all voting members of ACIP, removed key CDC staff supporting the committee, and announced eight new ACIP members, among other actions.

We highlight below HHS announcements details and selected responses. The scheduled ACIP meeting of June 25-27, 2025 will apparently proceed with these new members in place and under the agenda summary below:

Matters To Be Considered: The agenda will include discussions on anthrax vaccines, chikungunya vaccines, COVID-19 vaccines, cytomegalovirus (CMV) vaccine, Human papillomavirus (HPV) vaccine, influenza vaccines, Lyme disease vaccine, meningococcal vaccines, pneumococcal vaccines, Respiratory Syncytial Virus (RSV) vaccines for adults, and RSV vaccines for maternal and pediatric populations.

Recommendation votes are scheduled for COVID-19 vaccines, HPV vaccine, influenza vaccines, meningococcal vaccine, RSV vaccines for adults, and RSV vaccine for maternal and pediatric populations. Vaccines for Children (VFC) votes are scheduled for COVID-19 vaccines, HPV vaccine, influenza vaccines, and RSV vaccines. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit <https://www.cdc.gov/acip/meetings/index.html>.

We have issued an expression of concern [here](#).

::::::

CDC ACIP – HHS Removal/Retirement of All Voting Members; Removal of Key ACIP Staff

HHS Takes Bold Step to Restore Public Trust in Vaccines by Reconstituting ACIP

HHS Press Release

Washington, DC—JUNE 9, 2025— The U.S. Department of Health and Human Services (HHS) today took a bold step in restoring public trust, links to an external website, opens in a new tab by totally reconstituting the Advisory Committee for Immunization Practices (ACIP), an advisory committee that makes recommendations on the safety, efficacy, and clinical need of vaccines to the Centers for Disease Control and Prevention (CDC). Under the leadership of HHS Secretary Robert F. Kennedy, Jr., the agency removed the 17 sitting members of the ACIP committee and will replace them with new members currently under consideration.

"Today we are prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda," Secretary Kennedy said. "The public must know that unbiased science—evaluated through a transparent process and insulated from conflicts of interest—guides the recommendations of our health agencies."

As directed by President Trump's Restoring Gold Standard Science [executive order](#), [links to an external website](#), the new ACIP members will ensure that government scientific activities are informed by the most credible, reliable, and impartial scientific evidence available.

The Biden administration appointed all of the 17 sitting ACIP members. Thirteen of them were appointed in 2024. These appointments would have prevented the current administration from choosing a majority of the committee until 2028. The prior administration made a concerted effort to lock in public health ideology and limit the incoming administration's ability to take the proper actions to restore public trust in vaccines.

"A clean sweep is necessary to reestablish public confidence in vaccine science," Kennedy concluded. "ACIP's new members will prioritize public health and evidence-based medicine. The Committee will no longer function as a rubber stamp for industry profit-taking agendas. The entire world once looked to American health regulators for guidance, inspiration, scientific impartiality, and unimpeachable integrity. Public trust has eroded. Only through radical transparency and gold standard science, will we earn it back."

ACIP will [convene its next meeting](#), [links to an external website](#) June 25 through June 27 at CDC headquarters in Atlanta.

RFK Jr.: HHS Moves to Restore Public Trust in Vaccines

June 9, 2025 *Op-Ed, Wall Street Journal*

.....

Selected Analysis. Comments, Observations

AMA statement on Advisory Committee on Immunization Practices

American Medical Association Press Releases Jun 9, 2025

The following statement is attributable to: [Bruce A. Scott, M.D.](#), President, American Medical Association:

"For generations, the Advisory Committee on Immunization Practices (ACIP) has been a trusted national source of science-and data-driven advice and guidance on the use of vaccines to prevent and control disease. Physicians, parents, community leaders and public health officials rely on them for clinical guidance, public health information, and knowledge. Today's action to remove the 17 sitting members of ACIP undermines that trust and upends a transparent process that has saved countless lives. With an ongoing measles outbreak and routine child vaccination rates declining, this move will further fuel the spread of vaccine-preventable illnesses."

.....

National Academies Presidents Stress Importance of Science in Decision-Making About Vaccines

Statement | June 11, 2025

We are concerned about recent decisions by the U.S. secretary of health and human services that could undermine science-based decision-making about vaccines, including the dismissal of every member of the Advisory Committee on Immunization Practices (ACIP). Across administrations of both parties, the committee has had a profound, positive impact on the health of Americans by offering evidence-based guidance to the Centers for Disease Control and Prevention about vaccine use, playing a crucial role in determining who should get which vaccines and when.

Medical professionals have relied on ACIP's recommendations for decades, and we are troubled about the potential damage not only to an important source of scientific advice but also to the established processes for evidence-based policymaking on vaccines that have saved millions of lives.

The National Academies have an extensive body of work on vaccine access, safety, and scheduling. Decades of science demonstrate the safety of vaccines, reinforcing that they offer many health benefits and have few side effects. Vaccines are among the most rigorously tested and monitored medical breakthroughs in history. The risk of serious side effects from vaccination is extremely low; in contrast, many vaccine-preventable diseases carry far greater risks of illness or death.

In reconstituting the ACIP, we urge the HHS secretary to appoint experts who will adhere to the best available science and evidence to inform decisions about vaccines.

Marcia McNutt

President, National Academy of Sciences

John L. Anderson

President, National Academy of Engineering

Victor J. Dzau

President, National Academy of Medicine

.....

[AAP 'deeply troubled and alarmed' by ousting of CDC vaccine advisory committee](#)

American Academy of Pediatrics June 9, 2025

The AAP is "deeply troubled and alarmed" by the termination of all 17 voting members of a nonpartisan federal vaccine advisory committee and said their removal will "stoke distrust in lifesaving vaccines."

The Department of Health and Human Services (HHS) announced Monday it would replace the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) members just over two weeks before the group is scheduled to discuss COVID-19 and other vaccines.

"We are witnessing an escalating effort by the Administration to silence independent medical expertise and stoke distrust in lifesaving vaccines," AAP President Susan J. Kressly, M.D., FAAP, said in a statement. "Creating confusion around proven vaccines endangers families' health and contributes to the spread of preventable diseases."

The committee's voting members are independent medical and public health experts who do not work for the CDC. They meet at least three times a year to develop recommendations on how best to use vaccines after they are licensed or authorized by the Food and Drug Administration (FDA).

HHS Secretary Robert F. Kennedy Jr., who has a long history of anti-vaccine activism, accused the ACIP of being "a rubber stamp for industry profit-taking agendas" in a press release Monday. He did not offer evidence and said replacing the members will "reestablish public confidence."...

ACIP is scheduled to meet on June 25-27. The agenda includes votes on vaccines for COVID-19, HPV, flu, meningococcal disease and respiratory syncytial virus, all of which have been under discussion and review by current members for months.

ACIP's discussion of COVID-19 vaccines already was preempted by federal health officials who rolled out conflicting and incomplete recommendations of their own in recent weeks.

On May 20, the FDA announced new randomized, controlled trials would be needed for COVID vaccines for healthy people under 65 years. A week later, Kennedy said the CDC would remove the routine recommendations for COVID vaccination for healthy children and people who are pregnant, with no mention of an option for families who want a vaccine. The guidance evolved again several days later when the CDC added the option of shared clinical decision-making for children. These moves circumvented the typical process by which ACIP recommends who should receive the vaccines.

The AAP said ousting the committee "will cause even more confusion and uncertainty for families."

"Children and families must be able to access the immunizations they need to stay healthy," Dr. Kressly said. "Our vaccine infrastructure must include this critical step of nonpartisan, expert review and discussion of the science and clinical recommendations for individual vaccines. Families and children will be the ones to pay the price for this decision."

.....

RFK Jr. Conducts His Vaccine Purge

His claims about conflicts of interest proved to be nothing.

Opinion, Review & Outlook

Wall Street Journal, The Editorial Board

June 12, 2025 5:36 pm ET

We'd like to conclude we were wrong to oppose Robert F. Kennedy Jr. to run the Health and Human Services Department, but alas, no. The latest evidence is his purge of a vaccine advisory panel...

Mr. Kennedy says "the problem isn't necessarily that ACIP members are corrupt," though he implies it. "The problem is their immersion in a system of industry-aligned incentives and paradigms that enforce a narrow pro-industry orthodoxy." Ah, yes. His goal is to eliminate incentives to develop vaccines.

Louisiana Sen. Bill Cassidy, who voted to confirm Mr. Kennedy after some indecision, tweeted Tuesday that "Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion." Mr. Cassidy said he spoke with the secretary to ensure this won't be the case.

That's nice, but Mr. Kennedy seems more intent on vindicating his critics than pleasing the Senator.

.....

.....

CDC purges career officials from oversight of vaccine committee

CBS News, June 11, 2025 / 8:35 PM EDT

By Alexander Tin

Career officials at the Centers for Disease Control and Prevention responsible for overseeing the agency's committee of outside vaccine experts have been removed from their role in the process, multiple CDC officials tell CBS News.

News of their removal comes the same week Health and Human Services Secretary Robert F. Kennedy Jr. fired all the members of the CDC's Advisory Committee on Immunization Practices, known as ACIP, and replaced them with eight new picks that include close allies and COVID vaccine critics. The next meeting of the committee is coming up at the end of June...

Multiple federal health officials said the staffers removed from overseeing the panel included Dr. Melinda Wharton, the associate director for vaccine policy, and her team at the agency's National Center for Immunization and Respiratory Diseases.

A CDC spokesperson did not immediately respond to a request for comment.

.....

.....

CDC ACIP – HHS Secretary Announces New ACIP Members on X - June 11, 2025

[Secretary Kennedy](#) **[@SecKennedy](#)**

X 4:36 PM · Jun 11, 2025 *[email addresses identified in public domain added]*

On Monday, I took a major step towards restoring public trust in vaccines by reconstituting the Advisory Committee for Immunization Practices (ACIP).

I retired the 17 current members of the committee. I'm now repopulating ACIP with the eight new members who will attend ACIP's scheduled June 25 meeting.

The slate includes highly credentialed scientists, leading public-health experts, and some of America's most accomplished physicians. All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense. They have each committed to demanding definitive safety and efficacy data before making any new vaccine recommendations. The committee will review safety and efficacy data for the current schedule as well.

I'm proud to announce ACIP's new members:

Joseph R. Hibbeln, MD, is a psychiatrist and neuroscientist with a career in clinical research, public health policy, and federal service. As former Acting Chief of the Section on Nutritional Neurosciences at the National Institutes of Health, he led research on immune regulation, neurodevelopment, and mental health. His work has informed U.S. public health guidelines, particularly in maternal and child health. With more than 120 peer-reviewed publications and extensive experience in federal advisory roles, Dr. Hibbeln brings expertise in immune-related outcomes, psychiatric conditions, and evidence-based public health strategies. [[linkedin.com/in/joehibbeln](https://www.linkedin.com/in/joehibbeln); jhibbeln@mail.nih.gov]

Martin Kulldorff, MD, PhD, is a biostatistician and epidemiologist formerly at Harvard Medical School and a leading expert in vaccine safety and infectious disease surveillance. He has served on the Food and Drug Administration's Drug Safety and Risk Management Advisory Committee and the CDC's Vaccine Safety Subgroup of the Advisory Committee on Immunization Practices, where he contributed to national vaccine safety monitoring systems. Dr. Kulldorff developed widely used tools such as SaTScan and TreeScan for detecting disease outbreaks and vaccine adverse events. His expertise includes statistical methods for public health surveillance, immunization safety, and infectious disease epidemiology. He has also been an influential voice in public health policy, advocating for evidence-based approaches to pandemic response. [martin.kulldorff@gmail.com]

Retsef Levi, PhD, is the Professor of Operations Management at the MIT Sloan School of Management and a leading expert in healthcare analytics, risk management, and vaccine safety. He has served as Faculty Director of MIT Sloan's Food Supply Chain Analytics and Sensing Initiative and co-led the Leaders for Global Operations Program. Dr. Levi has collaborated with public health agencies to evaluate vaccine safety, including co-authoring studies on mRNA COVID-19 vaccines and their association with cardiovascular risks. His research has contributed to discussions on vaccine manufacturing processes, safety surveillance, and public health policy. Dr. Levi has also served on advisory committees and engaged in policy discussions concerning vaccine safety and efficacy. His expertise spans healthcare systems optimization, epidemiologic modeling, and the application of AI and data science in public health. Dr. Levi's work continues to inform national and international debates on immunization safety and health system resilience. [retsef@mit.edu]

Robert W. Malone, MD, is a physician-scientist and biochemist known for his early contributions to mRNA vaccine technology. He conducted foundational research in the late 1980s on lipid-mediated mRNA delivery, which laid the groundwork for later developments in mRNA-based therapeutics. Dr.

Malone has held academic positions at institutions including the University of California, Davis, and the University of Maryland, and has served in advisory roles for the U.S. Department of Health and Human Services and the Department of Defense. His expertise spans molecular biology, immunology, and vaccine development. [rwmalonemd@gmail.com]

Cody Meissner, MD, is a Professor of Pediatrics at the Geisel School of Medicine at Dartmouth and a nationally recognized expert in pediatric infectious diseases and vaccine policy. He has served as Section Chief of Pediatric Infectious Disease at Dartmouth-Hitchcock Medical Center and has held advisory roles with both the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). Dr. Meissner has been a voting member of the CDC's Advisory Committee on Immunization Practices and the FDA's Vaccines and Related Biological Products Advisory Committee, where he has contributed to national immunization guidelines and regulatory decisions. His expertise spans vaccine development, immunization safety, and pediatric infectious disease epidemiology. Dr. Meissner has also been a contributing author to American Academy of Pediatrics policy statements and immunization schedules, helping shape national standards for pediatric care. [H.Cody.Meissner@Dartmouth.edu]

James Pagano, MD, is a board-certified Emergency Medicine physician with over 40 years of clinical experience following his residency at UCLA. He has worked in diverse emergency settings, from Level 1 trauma centers to small community hospitals, caring for patients across all age groups, including infants, pregnant women, and the elderly. Dr. Pagano served on multiple hospital committees, including utilization review, critical care, and medical executive boards. He is strong advocate for evidence-based medicine. [fldoc2025@gmail.com]

Vicky Pebsworth, OP, PhD, RN, earned a doctorate in public health and nursing from the University of Michigan. She has worked in the healthcare field for more than 45 years, serving in various capacities, including critical care nurse, healthcare administrator, health policy analyst, and research scientist with a focus on public health policy, bioethics, and vaccine safety. She is the Pacific Region Director of the National Association of Catholic Nurses. She is a former member of the Food and Drug Administration's Vaccine and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee's 2009 H1N1 Vaccine Safety Risk Assessment Working Group and Vaccine Safety Working Group (Epidemiology and Implementation Subcommittees).

Michael A. Ross, MD, is a Clinical Professor of Obstetrics and Gynecology at George Washington University and Virginia Commonwealth University, with a career spanning clinical medicine, research, and public health policy. He has served on the CDC's Advisory Committee for the Prevention of Breast and Cervical Cancer, where he contributed to national strategies for cancer prevention and early detection, including those involving HPV immunization. With research experience in hormone therapies, antibiotic trials, and immune-related conditions such as breast cancer prevention, Dr. Ross has engaged in clinical investigations with immunologic relevance. He has advised major professional organizations, including the American College of Obstetricians and Gynecologists, and contributed to federal advocacy efforts around women's health and preventive care. His continued service on biotech and healthcare boards reflects his commitment to advancing innovation in immunology, reproductive medicine, and public health. [[linkedin.com/in/michael-ross-md-mha-375457](https://www.linkedin.com/in/michael-ross-md-mha-375457)]

4.5M Views at 14:51 - 14 June 2025

.....

Selected Analysis. Comments, Observations

[AAP: New CDC vaccine advisers a 'radical departure' from committee's mission](#)

American Academy of Pediatrics June 12, 2025

The eight new members of a critical federal vaccine committee “represent a radical departure” from its mission, the AAP said Wednesday.

Health and Human Services Secretary Robert F. Kennedy Jr. named the new members of the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) two days after firing all 17 voting members of the group...

“These appointments only confirm our fears and represent a radical departure from ACIP’s core mission,” said AAP President Susan J. Kressly, M.D., FAAP. “The American Academy of Pediatrics remains committed to ensuring the appropriate expertise informs science-based vaccine recommendations and that children’s access to immunizations is preserved.”...

“We are witnessing an escalating effort by the Administration to silence independent medical expertise and stoke distrust in lifesaving vaccines,” Dr. Kressly said earlier this week. “Creating confusion around proven vaccines endangers families’ health and contributes to the spread of preventable diseases.”...

In addition to studying new vaccines, Kennedy said he has tasked the new ACIP members with reviewing the safety and efficacy of the immunization schedules.

.....

Kennedy’s new CDC panel includes members who have criticized vaccines and spread misinformation

Associated Press, June 12, 2025

By MIKE STOBBE

.....

Meet RFK Jr.’s New Vaccine Advisers

With one exception, his committee members seem to know little about vaccines.

Opinion, Review & Outlook

Wall Street Journal, The Editorial Board

June 12, 2025 5:36 pm ET

We didn’t think anyone could do more to damage trust in public health institutions than Anthony Fauci, but Robert F. Kennedy Jr. is giving it a whirl. See the eccentric crew the Health and Human Services Secretary has tapped to advise the department on vaccines...

Mr. Kennedy’s only pick with any substantive vaccine expertise appears to be pediatrician Cody Meissner, who previously served on government vaccine advisory panels and has espoused the benefits of vaccines, including in a 2022 paper in the *New England Journal of Medicine*. Consider him the committee’s contrarian.

RFK Jr. is playing into his critics’ hands with his picks. A danger is that he uses the panel to put a government imprimatur on his anti-vaccine views and assist his lawyer friends. The committee determines children’s vaccine schedules, and it influences which shots are covered under the government’s no-fault vaccine injury compensation program.

Mr. Kennedy claimed in his op-ed in these pages that reconstituting the advisory committee would restore public trust in vaccines. He’s on a path to do the opposite.

.....

A closer look at the new members of the CDC vaccine advisory panel

[Several of those picked by RFK Jr. have a history of vaccine skepticism](#)

STAT, June 11, 2025

.....
.....

Featured Journal Content

[Changed Recommendations for COVID-19 Vaccines for Children and Pregnant Women - A Failure of Process, Policy, and Science](#)

Viewpoint

Lawrence O. Gostin, JD; Dorit Reiss, PhD; Paul A. Offit, MD

JAMA, Published Online: June 13, 2025 doi: 10.1001/jama.2025.10658

On May 27, Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr announced in a 58-second [video](#) on the platform X (formerly Twitter) that he is rescinding the recommendation for COVID-19 vaccines for healthy children aged 6 months to 17 years and pregnant women. Secretary Kennedy was accompanied by the US Food and Drug Administration (FDA) commissioner and director of the National Institutes of Health (NIH), but no one from the Centers for Disease Control and Prevention (CDC), which was unaware of the policy change. The secretary disregarded decades-long processes and norms of good administration. While the HHS secretary has final legal authority to approve vaccine recommendations, the failure to follow a deliberative process may be challenged...

...Vaccine oversight is allocated between the FDA and CDC, each with statutorily defined functions.⁵ The US Congress charged the FDA to license or authorize vaccines based on scientific studies of their safety and effectiveness. The agency also determines labeling requirements for vaccines, including their intended purposes and risks. Yet, the CDC sets adult and childhood immunization schedules based on ACIP recommendations. ACIP reviewed the data for COVID-19 vaccines for children and pregnant women. CDC issued recommendations after lengthy public discussion, accompanied by heavily referenced scientific studies. CDC recommendations for COVID-19 vaccines are supported by the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists.

Secretary Kennedy's process blurs lines of legal authority. Despite the secretary's power to issue final vaccine recommendations, HHS circumvented ACIP and the CDC. The FDA and NIH have limited roles in vaccine recommendations through their ex officio (nonvoting) representation in ACIP meetings. Congress has delegated authority to ACIP to make vaccine recommendations under the Affordable Care Act (§2713)⁶ and the 21st Century Cures Act (§3091-3092).⁷ Statutory delegation to ACIP exists to preserve agency accountability and underscore the importance of independent scientific evaluation. The secretary's direct involvement is exceedingly rare.

Administrative law requires agencies to "examine the relevant data and articulate a satisfactory explanation for its action." Yet, the secretarial directive and short video offer no clear reasoning for overturning current agency findings. The NIH director stated it is "common sense" that COVID-19 vaccines are not effective for children. In a recent article, the FDA listed pregnancy as a high-risk condition for COVID-19, contradicting the video and directive. Under longstanding judicial review standards, a change of administration does not justify a change in policy. The video suggests a political motive, which is unlikely to withstand future legal challenges...

.....
.....

Polio – PHEIC

[Polio this week – 11 June 2025](#)

Headlines *[Selected]*

- **Importance of vaccine research for post-eradication era**

As the world prepares for a polio-free future, scientists are working on next-gen vaccines using virus-like particles (VLPs), an initiative launched and coordinated by WHO. In Vaccine Insights, Professor Nicola Stonehouse, from the University of Leeds, reflects on her collaboration with the GPEI and how this breakthrough could shape post-certification strategy. [\[Read the interview\]](#)

- **More Than Polio: How Somalia's Vaccine Drive is Securing a Healthier Future**

In a powerful show of political will, Somalia vaccinated nearly 1.4 million children last week—protecting them not just against polio, but also measles and pneumonia. This integrated effort highlights the broader impact of polio eradication on strengthening health systems. [\[Learn more\]](#)

- **New SAGE Report Calls for Bold Action on Polio and Routine Immunization**

The latest report from WHO's Strategic Advisory Group of Experts on immunization (SAGE) urges stronger global action on polio eradication—highlighting concerns over rising wild virus cases, variant poliovirus spread into new regions, and the urgent need to reach zero-dose children. It backs bOPV cessation plans, endorses a new risk-assessment framework for IPV-only schedules, and updates key vaccine recommendations. [\[Read the full report\]](#)

Summary of new polioviruses this week, cases and positive environmental isolates:

- Angola: one cVDPV2 case
- Benin: one cVDPV2 case
- Niger: one cVDPV2 case

.....
.....

mPox – PHEIC

[Fourth meeting of the International Health Regulations \(2005\) Emergency Committee regarding the upsurge of mpox 2024 – Temporary recommendations](#)

9 June 2025 *Statement*

The Director-General of the World Health Organization (WHO), following the fourth meeting of the International Health Regulations (2005) (IHR) [Emergency Committee regarding the upsurge of mpox 2024](#), held on 5 June 2025, from 12:00 to 17:00 CEST, **concurs with its advice that the event continues to meet the criteria of a public health emergency of international concern** and, considering the advice of the Committee, he is **hereby issuing a revised set of temporary recommendations**.

Temporary recommendations

These temporary recommendations are issued to States Parties experiencing the transmission of monkeypox virus (MPXV), including, but not limited to, those where there is sustained community transmission, and where there are clusters of cases or sporadic travel-related cases of MPXV clade Ib.

They are intended to be implemented by those States Parties in addition to the current [standing recommendations for mpox](#), valid until 20 August 2025.

In the context of the global efforts to prevent and control the spread of mpox disease outlined in the [WHO Strategic framework for enhancing prevention and control of mpox: 2024–2027](#), the aforementioned standing recommendations apply to all States Parties.

All current WHO interim technical guidance can be accessed on [this page](#) of the WHO website. WHO evidence-based guidance has been and will continue to be updated in line with the evolving situation,

updated scientific evidence, and WHO risk assessment to support States Parties in the implementation of the WHO Strategic Framework for enhancing mpox prevention and control.

Pursuant to Article 3 Principle of the International Health Regulations (2005) (IHR), the implementation of these temporary recommendations, as well as of the standing recommendations for mpox, by States Parties shall be with full respect for the dignity, human rights and fundamental freedoms of persons, in line with the principles set out in Article 3 of the IHR.

[Excerpt]

...Vaccination

Continue to prepare for and implement targeted use of vaccine for “Phase 1-Stop the outbreak” (as defined in the WHO Mpox global strategic preparedness and response plan (2025)) through the identification of the lowest administrative level reporting cases (hotspots) and targeting those groups at high risk of mpox exposure to interrupt sustained community transmission. (EXTENDED, with rephrasing and updated reference)

Develop and implement plans for vaccination in the context of an integrated response at the lowest administrative level reporting cases for people at high risk of exposure (e.g., contacts of cases of all ages, health and frontline workers, and other groups at risk such as those with multiple sexual partners and sex workers in endemic and non-endemic areas). This entails a targeted integrated response, including active surveillance and contact tracing; agile adaptation of immunization strategies and plans to the local context including dose-sparing options (single dose/fractional dosing) in the context of limited availability of vaccines; proactive community engagement to generate and sustain demand for and trust in vaccination; close monitoring of mpox vaccination activities, coverage and adverse events following immunization (AEFI); assessment of vaccine effectiveness; and documenting lessons learned and their implementation. (MODIFIED)...

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 14 June 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

[Fourth meeting of the International Health Regulations \(2005\) Emergency Committee regarding the upsurge of mpox 2024 – Temporary recommendations](#)

9 June 2025 Statement

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

No new digest content identified.

WHO Region of the Americas PAHO

:: 13 Jun 2025

Eastern Caribbean launches regional project to strengthen pandemic preparedness and response

With support from the Pandemic Fund and in collaboration with PAHO/WHO, FAO, and the World Bank, six countries unite to build more resilient health systems Washington, DC, 13 June 2025 (PAHO/WHO)- A landmark initiative to boost pandemic preparedness and response in the Eastern Caribbean was officially launched this week in Castries, Saint Lucia,...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 12 June 2025 Media release

Chronic respiratory diseases: more than 80 million affected and many more undiagnosed, warns new WHO and European Respiratory Society report

:: 12 June 2025 News release

WHO designates new collaborating centre on public health leadership and workforce development

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

.....

Weekly Epidemiological Record

13 June 2025, Vol. 100, No. 24/25, pp. 239–250

https://hq_weeklyepidemiologicalrecord.cmail20.com/t/d-l-skistl-ijdtklujh-r/

:: 239 Skin health for all: update on skin neglected tropical diseases with a focus on Buruli ulcer and yaws

.....

New WHO Publications

<https://www.who.int/publications>

Selected

13 June 2025

[**Mekong Malaria Elimination Programme epidemiology summary, volume 29, January–March 2025**](#)

13 June 2025

[**Respiratory syncytial virus sequencing considerations for an expanded Global Influenza Surveillance and...**](#)

12 June 2025

[**Evaluation of WHO 13th General Programme of Work: Executive summary**](#)

12 June 2025

[**Joint evaluation of the Global Action Plan for Healthy Lives and Well-being for All: Report**](#)

10 June 2025

[**Use of computer-aided detection software for tuberculosis screening: WHO policy statement**](#)

.....

.....

Editor's Note:

As a service to readers, we employ bolded red text below to identify potentially problematic content and observations added by the Editor.

USA – HHS, FDA, CDC+

White House

Presidential Actions – Executive Orders

No new digest content identified.

HHS

News

[**HHS Takes Bold Step to Restore Public Trust in Vaccines by Reconstituting ACIP**](#)

June 9, 2025 *Press Release*

[**RFK Jr.: HHS Moves to Restore Public Trust in Vaccines**](#)

June 9, 2025 *Op-Ed*

NIH [to 14 June 2025]

<http://www.nih.gov/>

News Releases

No new digest content identified

FDA

Press Announcements

No new digest content identified

CDC/ACIP [to 14 June 2025]

<http://www.cdc.gov/media/index.html>

Latest News

No new digest content identified

ACIP Meetings [to 14 June 2025]

Next ACIP Meetings

:: June 25-27 [Federal Register Notice - June 6, 2025]

:: October 22-23

MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

June 12, 2025 / No. 21

[PDF of this issue](#)

No new digest content identified

FDA VRBPAC

Advisory Committee Calendar

No new meetings scheduled.

National Vaccine Program

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV Meeting - TBD

We are rescheduling the ACCV Meetings originally planned for Wednesday, January 29, 2025, and Thursday, January 30, 2025. Once the new dates are confirmed, information will be available here on the ACCV website and announced in the Federal Register.

.....
.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[Slow increases in COVID-19 observed across EU/EEA as a new variant emerges](#)

13 Jun 2025

Surveillance and monitoring

[Communicable disease threats report, 7-13 June 2025, week 24](#)

13 Jun 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7-13 June 2025 and includes updates on respiratory virus epidemiology in the EU/EEA, West Nile virus, measles, autochthonous chikungunya virus, mass gathering monitoring (Jubilee of 2025 in Italy, Hajj – Kingdom of Saudi Arabia, EuroPride - Portugal, invasive pneumococcal disease, influenza A(H5N1), Risk Assessment under production.

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee \(PRAC\) 2-5 June 2025](#)

EMA concludes review of semaglutide medicines and starts review of two chickenpox vaccines
6 June 2025

.....
.....

Africa CDC [to 14 June 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

[Communique of the Ministerial Consultations on Local Manufacturing of Health Products](#)

13 June 2025

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 14 June 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 14 June 2025]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-06-13 / No. 24

[PDF of this issue](#)

:: [Preplanned Studies: Trends in Life Expectancy of HIV-Infected Patients Receiving Antiretroviral Therapy — China, 2013–2023](#)

:: [Recollection: Impact of Comprehensive Strategy on Mortality in Heterosexually Transmitted HIV-Infected Individuals — Liangshan Prefecture, Sichuan Province, China, 2008–2024](#)

HTML(257) PDF 445KB(13)

.....
.....

[Contents \[click to move among sections\]](#)

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 14 June 2025]

<https://alleninstitute.org/news-press/>

Recent News

No new digest content identified.

BMGF - Gates Foundation [to 14 June 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

CARB-X [to 14 June 2025]

<https://carb-x.org/>

News

No new digest content identified.

Chan Zuckerberg Initiative [to 14 June 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 14 June 2025]

<http://cepi.net/>

CEPI News, Blog

No new digest content identified.

CIDRAP – Vaccine Inventory Project

<https://www.cidrap.umn.edu/vaccine-integrity-project>

News, Viewpoints

[**RFK's reckless firing of CDC vaccine advisors not supported by evidence \(June 10, 2025\)**](#)

Vaccine Integrity Project Staff and Advisers

June 10, 2025

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 14 June 2025]

<https://cioms.ch/>

News; Publications; Events

[**CIOMS Glossary of ICH Terms & Definitions**](#)

A glossary of ICH terms and definitions has been compiled by [CIOMS](#) from across ICH Guidelines. For information on this helpful CIOMS initiative, please visit the [CIOMS website](#), where the glossary is freely available for download, providing a useful resource for both CIOMS and ICH Stakeholders and Working Groups.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 14 June 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 14 June 2025]

<https://dndi.org/press/press-releases/>

Press Releases

13 Jun 2025

Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries

13 Jun 2025

K-MEDI and DNDi have initiated collaborative R&D to develop a treatment for neglected diseases

K-MEDI has been chosen as a collaborating institute for developing an affordable and globally accessible medicine for river blindness. The project is led by DNDi and supported by a 3.2 billion KRW grant from the RIGHT Foundation.

Duke Global Health Innovation Center [to 14 June 2025]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 14 June 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 14 June 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 14 June 2025]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Fondation Merieux [to 14 June 2025]

<http://www.fondation-merieux.org/>

News, Events

Événement co-organisé par la Fondation Mérieux

3ème édition du cours avancé sur l'épidémiologie dans les situations d'urgence complexes

7-11 juillet 2025 - Centre des Pensières, Veyrier-du-Lac (France)

Gates Medical Research Institute [to 14 June 2025]

<https://www.gatesmri.org/news>

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications

No new digest content identified.

Gavi [to 14 June 2025]

<https://www.gavi.org/>

Press Releases

13 June 2025

Statement on the first joint GPEI-Gavi Board Meeting

12 June 2025

Gavi and Asian Development Bank sign new partnership to boost health financing for immunisation

- The Asian Development Bank (ADB) and Gavi sign a new cooperation agreement to help countries expand immunisation coverage and strengthen health systems
- This agreement comes at a pivotal moment as ADB is scaling up its lending capacity, and Gavi embarks on its most ambitious five-year strategy to date
- This week, Gavi published a new report outlining its plans to deepen collaboration with development banks in order to unlock capital for immunisation

GE2P2 Global Foundation [to 14 June 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review - Current edition](#)

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 25 May 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – May 2025](#)

GHIT Fund [to 14 June 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 14 June 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 14 June 2025]

<https://www.glopid-r.org/news/>

No new digest content identified.

Hilleman Laboratories [to 14 June 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 14 June 2025]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 14 June 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 14 June 2025]

<https://www.iavi.org/>

Press Releases, Features

[Summary report: Towards a proposal for a novel TB vaccine R&D financing initiative](#)

This report captures the key insights from a roundtable discussion, convened on 14 October 2024 at the World Health Assembly in Berlin, focused on innovative financing mechanisms to support the late-stage development of tuberculosis (TB) vaccines. The session aimed to harness expert perspectives on potential financing strategies and criteria that could be applied to TB vaccine development, with three thematic recommendations emerging.

[Technical brief: Towards a proposal for a novel TB vaccine R&D financing initiative](#)

This brief outlines key considerations and tentative recommendations towards a new financing initiative for TB vaccines R&D, with a focus on late-stage candidates. It is designed to provide background information to help stimulate debate during the workshop series on late-stage TB vaccine R&D financing R&D. The contents of this paper and the outputs of the workshop series, which includes engagement with a range of key stakeholders, will inform the development of a validated proposal for late-stage TB vaccine R&D financing.

INSERM [to 14 June 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 14 June 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

12 June 2025

ICH E21 Step 2 Presentation Now Available on the ICH Website

The ICH E21 draft Guideline on “Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials” reached Step 2b of the ICH Process in May 2025 and has entered the consultation

ICRC [to 14 June 2025]

<https://www.icrc.org/en/news>

Latest press releases and statements [Selected]

Israel and the Occupied Territories: ICRC extremely concerned about inability of Nasser Medical Complex to operate amid evacuation orders

Statement 14-06-2025

Middle East: ICRC calls for de-escalation and protection of civilians amid rising tensions

News release 13-06-2025

Israel and the occupied territories: Red Cross Field Hospital receives twelve mass casualty events in two weeks

Statement 10-06-2025

IFFIm [to 14 June 2025]

<http://www.iffim.org/>

Press Releases/Announcements

IFFIm sterling bond takes total vaccine bond issuance over US\$ 10 billion milestone

11 Jun 2025

The International Finance Facility for Immunisation (IFFIm) today announced the settlement of its £300 million, 3-year 4.25% fixed-rate bond that was announced on 3 June. This is the third bond issue in pound sterling and a powerful reaffirmation of investor confidence in vaccine bonds as a tool for global health impact.

With this latest transaction, IFFIm’s total issuance since its founding in 2006 now exceeds US\$ 10 billion, supporting life-saving immunisation programmes in lower-income countries through its partner, Gavi, the Vaccine Alliance.

This latest bond issue received strong demand from a broad base of global investors—almost 90 percent from UK-based asset managers and institutional investors in the City of London—demonstrating continued support and momentum from the UK behind socially responsible investment in global health. Historically, past bond issuances have included high-profile repeat investors Legal & General Investment Management (UK) and Record Financial Group (UK).

“IFFIm’s success is a testament to the UK’s leadership in harnessing the power of financial markets for global good,” said Ken Lay, Chair of the IFFIm Board. “This bond underscores not only the deep trust of our investors but also the critical role of the UK’s private sector in sustaining vaccine equity worldwide.”...

IFRC [to 14 June 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [to 14 June 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [to 14 June 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 14 June 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

[19th International Congress of Immunology](#)

Vienna, August 17-22, 2025.

IVAC [to 14 June 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

U.S. Measles Tracker

[Tracking Measles Cases in the U.S.](#)

Updated June 13, 2025

IVI [to 14 June 2025]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 14 June 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 14 June 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Sudan

Children in Darfur urgently need immunisation as measles spreads

Press Release 10 Jun 2025

Chad

Chad: MSF tackles logistical challenges to vaccinate 500,000 people against diphtheria

Project Update 10 Jun 2025

National Academy of Medicine - USA [to 14 June 2025]

<https://nam.edu/programs/>

News [Selected]

Jun 11, 2025

National Academies Presidents Stress Importance of Science in Decision-Making About Vaccines

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 14 June 2025]

<https://www.nationalacademies.org/newsroom>

News

National Academies Presidents Stress Importance of Science in Decision-Making About Vaccines

In a statement, the presidents of the National Academies of Sciences, Engineering, and Medicine express concern about the dismissal of every member of the CDC's Advisory Committee on Immunization Practices, which could undermine science-based decision-making about vaccines.

Date 2025-06-11

Type Statement

NAS President Says U.S. Science Is Facing 'Pessimistic' Future, Urges Changes to Regain Leadership in Science

In her recent State of the Science address, National Academy of Sciences President Marcia McNutt warned of a "pessimistic" future for U.S. science, from federal budget cuts to a burdensome regulatory environment to a loss of international talent, and proposed a range of actions to strengthen the research enterprise.

Date 2025-06-09

PATH [to 14 June 2025]

<https://www.path.org/media-center/>

Newsroom [Selected]

No new digest content identified.

Sabin Vaccine Institute [to 14 June 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

Press Releases

No new digest content identified.

UNAIDS [to 14 June 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Press Release

UNAIDS Executive Director commends South Africa's political and financial commitment to end AIDS, and its leadership in the G20

GENEVA/JOHANNESBURG, 13 June 2025–

UNICEF [to 14 June 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Remarks 10 June 2025

UNICEF Executive Director Catherine Russell's opening remarks at the Annual Session of the UNICEF Executive Board

"Excellencies, distinguished delegates, colleagues, "It is a pleasure to welcome you to the 2025 Annual Session of the UNICEF Executive Board. Let me begin by extending heartfelt thanks to you, Ambassador Hikmat for your leadership as President of the Executive Board, and indeed to the entire Bureau. We deeply app...

"Our staff continue to serve with extraordinary dedication, often in some of the most challenging environments. I want to take this opportunity to thank them. It is their tireless efforts that drive our impact and uphold the values we all share.

"Thanks to their work, UNICEF achieved important progress in 2024:

"We delivered over 1.5 billion polio vaccine doses to 87 countries, contributing to a 25 per cent reduction in global polio cases.

"We provided early detection services of wasting to 251 million children under five, and treatment for 9.3 million children with severe acute malnutrition.

"We delivered education support for 26 million out-of-school children and adolescents — including 9 million in humanitarian crises and 3.7 million children on the move.

"And nearly 33 million people gained access to safe water through the work of UNICEF and our partners, with impressive gains in Latin America and the Caribbean, and the Middle East and North Africa.

"In humanitarian action, 2024 was another year of profound need and wide-scale response. We reached more than 56 million people — including 31 million children — with essential humanitarian assistance across the globe. This included responses to crises in Afghanistan, the Democratic Republic of the Congo, Gaza, Haiti, the Horn of Africa, Sudan, and Ukraine...

We must protect this progress, but the sudden and sharp global funding crisis puts our critical work at tremendous risk. In 2026, UNICEF projects at least a 20 per cent reduction in total income from 2024 levels, with a 26 per cent drop from the public sector.

"This decline is not just a UNICEF crisis — it is impacting the entire humanitarian and development ecosystem, with grave implications for children worldwide. In 2026, UNICEF is expecting only \$250 million dollars from the public sector in regular resources. This is the lowest figure in more than a decade. These regular resources contribute to our institutional budget, which underpins our country programmes and critical oversight functions...

Unitaid [to 14 June 2025]

<https://unitaid.org/>

Featured News

News releases

Unitaid supports uptake of objective blood loss measurement devices to advance lifesaving care for postpartum hemorrhage in resource-limited settings

11 June 2025

Vaccine Equity Cooperative [nee Initiative] [to 14 June 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccine Confidence Project [to 14 June 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 14 June 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter May 2025

Wellcome Trust [to 14 June 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 14 June 2025]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 14 June 2025]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 14 June 2025]

<https://www.wfpha.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 14 June 2025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [OIE] [to 14 June 2025]

<https://www.oie.int/>

Press Releases, Statements

No new digest announcements identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 14 June 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest announcements identified.

BIO [to 14 June 2025]

<https://www.bio.org/press-releases>

Press Releases

BIO Statement on HHS Dismissal of CDC Advisory Committee Members

June 9, 2025

WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today's dismissal of the voting members of the CDC Advisory Committee on Immunization Practices: ... We are greatly concerned about the uncertainty created by the abrupt dismissal of the serving committee members and the loss of years of experience, especially less than three weeks before the next ACIP meeting, with consequential votes on recommendations that will affect Americans' access to RSV, flu, HPV and other important vaccines...

DCVMN – Developing Country Vaccine Manufacturers Network [to 14 June 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 14 June 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 14 June 2025]

<https://ifpma.org/>

News, Statements [Selected]

Press release 12 Jun 2025

Pharmaceutical industry calls on G7 to prioritize innovation as strategic pillar for health, growth, and security

Geneva and Ottawa – Ahead of the upcoming G7 Leaders' Summit, the global pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Innovative Medicines Canada (IMC), are calling on G7 governments to place health and innovation at the top of their agenda at the upcoming leaders' summit.

In an open letter published today, IFPMA and IMC, together with their members, have reaffirmed the industry's commitment to ongoing collaboration, including through Canada's G7 Presidency, to improve patient outcomes, strengthen health systems, boost economic growth, and support national security...

Report 2 Jun 2025

From protection to prevention: The power of immunization for people living with non-communicable diseases

The policy report From protection to prevention: The power of immunization for people living with non-communicable diseases has been commissioned to The Health Policy Partnership (HPP) by IFPMA.

International Alliance of Patients' Organizations – IAPO [to 14 June 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

Calling for health and access to health for all as a priority in the upcoming G7 Leaders' Summit – An IGBA perspective (June 2025)

The International Generic and Biosimilar medicines Association (IGBA), being the global voice of generic and biosimilar medicines industries, calls for G7 countries to consider health and access to health as a priority in its upcoming discussions, to be held in Alberta, Canada.

PhRMA [to 14 June 2025]

<http://www.phrma.org/>

Press Releases

Calling for health and access to health for all as a priority in the upcoming G7 Leaders' Summit – An IGBA perspective (June 2025)

The International Generic and Biosimilar medicines Association (IGBA), being the global voice of generic and biosimilar medicines industries, calls for G7 countries to consider health and access to health as a priority in its upcoming discussions, to be held in Alberta, Canada.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases

AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research PUBLISHED 13 June 2025

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.

Under the terms of the agreement, AstraZeneca and CSPC agree to discover and develop pre-clinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases...

Bavarian Nordic

Latest News

Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine.

June 12, 2025

Bharat Biotech

Press Releases

Jun 12: Bharat Biotech to Advance Development of GSK's Shigella Vaccine Candidate for Severe Bacterial Diarrhoea

:: Bharat Biotech in-licenses altSonflex1-2-3, a promising Shigella vaccine candidate, from GSK for continued clinical development and scale-up

:: Shigella is the leading bacterial cause of diarrhoeal disease in children under five, with a significant impact in low- and middle-income countries

:: Innovative Generalized Modules for Membrane Antigens (GMMA) technology and strong early trial results signal significant potential to reduce disease burden and address rising antimicrobial resistance (AMR)

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases

12 June 2025

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

:: Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its oncology strategy

:: Acquisition of CureVac will complement BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News -

June 12, 2025

[BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer](#)

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

13 June 2025

[GSK's RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older](#)

12 June 2025

[GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development](#)

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified

Merck

News releases

[Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate](#)

June 12, 2025

:: MOBILIZE-1 is the first Phase 3 study being initiated for V181 as part of a planned robust clinical development program

:: Study will evaluate a single dose of V181 for the prevention of dengue disease caused by any of the four serotypes of the dengue virus regardless of previous exposure

Moderna

Press Releases

June 12, 2025

[Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease](#)

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Jun 11, 2025 COVID-19, Seasonal influenza

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases

June 9, 2025

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: [*Pre-Print Servers*](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 6: E393-477

<https://journalofethics.ama-assn.org/issue/embodiment-art-practice>

Issue Theme: Embodiment in Art Practice

[Reviewed earlier]

American Journal of Human Genetics

Jun 05, 2025 Volume 112 Issue 6 p1249-1496

<https://www.cell.com/ajhg/current>

This month in The Journal

Alyson B. Barnes, Sara B. Cullinan

Within the field of prenatal genetic diagnosis, there is ongoing debate about whether fetal genomic sequencing (GS) should be offered for all pregnancies or only when a genetic disorder is suspected. Currently, the International Society of Prenatal Diagnosis recommends exome sequencing (ES) only in the presence of sonographic abnormalities. However, many treatable genetic disorders do not present with ultrasound abnormalities. In fact, recent studies have found that 0.6%–2.7% of sonographically normal fetuses harbor pathogenic or likely pathogenic variants expected to cause genetic disease, making a case for offering fetal GS to all pregnant individuals.

[Reviewed earlier]

American Journal of Infection Control

June 2025 Volume 53 Issue 6 p669-746

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

May 2025 Volume 68 Issue 5 p859-1050

<https://www.ajpmonline.org/current>
[Reviewed earlier]

American Journal of Public Health

June 2025 115(6)
<http://ajph.aphapublications.org/toc/ajph/current>
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 112 (2025): Issue 6 (Jun 2025)
<https://www.ajtmh.org/view/journals/tpmd/112/6/tpmd.112.issue-6.xml>
[Reviewed earlier]

Annals of Internal Medicine

May 2025 Volume 178, Issue 5
<https://www.acpjournals.org/toc/aim/current>
[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 344 July 2025
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/344/suppl/C>
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>
(Accessed 14 June 2025)
[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>
(Accessed 14 June 2025)
[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>
(Accessed 14 June 2025)
[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>
(Accessed 14 June 2025)
[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 14 June 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 14 June 2025)

No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 14 June 2025)

No new digest content identified]

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 14 June 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

June 2025 - Volume 30 - 3

<https://ebm.bmj.com/content/30/3>

[Reviewed earlier]

BMJ Global Health

May 2025 - Volume 10 - 5

<https://gh.bmj.com/content/10/5>

[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - May 2025

<https://thebulletin.org/magazine/2025-03/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 5, May 2025, 285-348

<https://www.who.int/publications/journals/bulletin/>

[Reviewed earlier]

Cell

May 29, 2025 Volume 188 Issue 11 p2829-3096

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 4 July 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 117, Issue 5 Pages: 1149-1470 May 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

White Paper

ICH M12 Drug Interaction Studies: Summary of the Efforts to Achieve Global Convergence

Kellie Reynolds, Xinning Yang, Sheila Annie Peters, Vikram Sinha, Helen Heymann, Luiza Novaes Borges, Heidi J. Einolf, Shujun Fu, Motohiro Hoshino, Li Li, Elin Lindhagen, So Miyoshi, Katsuhiko Mizuno, Venkatesh Pilla Reddy, Matthias S. Roost, Ryota Shigemi, Xiaolu Tao, Meng-Syuan Yang, Sylvia Zhao, Carolien Versantvoort, Akihiro Ishiguro, Rajanikanth Madabushi

Pages: 33-44

First Published: 19 March 2025

Abstract

The ICH M12 Guideline on Drug Interaction Studies is the result of a harmonization process led by global regulatory and industry experts with experience in drug–drug interaction (DDI) assessments and interpretation. The Expert Working Group (EWG) built on areas of regional consensus and identified solutions to topics lacking initial consensus. This article describes the topics addressed in the guideline, with emphasis on areas that required extensive discussion. It mentions topics that were the subject of comments during the public consultation period. The scope of the guideline is pharmacokinetic DDIs mediated by metabolic enzymes and drug transporters. It describes in vitro and clinical DDI studies and predictive modeling evaluations conducted during drug development. The understanding of DDI liability, in the context of the intended patient population, guides the development of risk management strategies. In the in vitro area, this article describes the considerations that support the use of experimentally measured fraction unbound for drugs with > 99% protein binding, modification of several in vitro criteria used to recommend a clinical DDI study and modification of DDI assessment for metabolites. Areas of close attention by the EWG for clinical evaluation included the use of endogenous biomarker studies, the use of nested DDI studies, and the establishment of no-effect boundaries. The article indicates the value of describing a general process for evaluating UGT-mediated DDIs, although specific criteria are not available. The guideline describes the current understanding of the role of predictive modeling in DDI evaluation. The topics described in this article can stimulate further growth in the science of DDI assessments.

Clinical Therapeutics

June 2025 Volume 47 Issue 6 p403-462

<http://www.clinicaltherapeutics.com/current>

Editorial

Mycobacterium tuberculosis: A Resurgent Scourge Writing Another Chapter in Its History

Paul Beninger

Published online: April 22, 2025

p403-404

Clinical Trials

Volume 22 Issue 3, June 2025

<https://journals.sagepub.com/toc/ctja/22/3>

Articles

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 14 June 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 152 May 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/152/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 3 / June 2025

<https://www.liebertpub.com/toc/crispr/8/3>

Editorial Free

[**Facing Systemic Uncertainty, Can the CRISPR Community Stay the Course?**](#)

[Rodolphe Barrangou](#)

Page:165

Published Online:10 June 2025

Review Article

[**Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges**](#)

[Henna Butt, Mamatha Mandava, and David Jacobsohn](#)

Pages:174–188

Published Online:12 May 2025

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

June 2025 - Volume 38 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 14 June 2025]

[No new digest content identified]

Cytotherapy

May 2025 Volume 27 Issue 5 p565-670

<https://www.isct-cytotherapy.org/current>

Review

Sickle cell disease gene therapy drug expenses and reimbursement: a litmus test for commercial pricing strategy and patient access for curative therapies

Bambi J. Grilley, Ashley Hume, Jacques Galipeau

Published online: January 23, 2025

ABSTRACT

Durable gene therapies newly approved by the Food and Drug Administration for sickle cell disease offer the promise of cure with subsequent improvement in quality of life through avoidance of repeated hospitalizations and worsening of disabilities in these patients. In the United States, following Food and Drug Administration approval, lovotibeglogene autotemcel (Lyfgenia, bluebird bio, Inc, Sommerville, MA, USA) and exagamglogene autotemcel (Casgevy, Vertex Pharmaceuticals Inc, Boston, MA, USA) were launched in 2024 for treatment of patients 12 years and older with frequent vaso-occlusive crises. Here we will discuss the first treatment with lovotibeglogene as a test case serving to highlight the multiple drug reimbursement pathways in the United States for cell and gene products for orphan disorders and their impact on patient adoption and access.

Developing World Bioethics

Volume 25, Issue 2 Pages: 81-163 June 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 35, Issue 4, 2025

<https://www.tandfonline.com/toc/cdip20/35/4?nav=tocList>

[New issue; No digest content identified]

Development Policy Review

Volume 43, Issue 3 May 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 49, Issue 3 July 2025
<https://onlinelibrary.wiley.com/toc/14677717/current>
[Reviewed earlier]

eBioMedicine

Volume 115 May 2025
<https://www.sciencedirect.com/journal/ebiomedicine/vol/115/suppl/C>
[Reviewed earlier]

EMBO Reports

Volume 26 Issue 1027 May 2025
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 5—May 2025
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 50 March 2025
<https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 3, Pages: 1-45, May–June 2025
<https://onlinelibrary.wiley.com/toc/25782363/current>
Undue inducement :: Deception in research
[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 4 - Winter 2024
<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>
[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024
<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>
[Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 2, April 2025

<https://academic.oup.com/eurpub/issue/35/2>

[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

May/June 2025 Volume 104, Number 3

<https://www.foreignaffairs.com/issues/2025/104/3>

[Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 14 June 2025]

[No new digest content identified]

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 14 June 2025]

[No new digest content identified]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 14 June 2025]

Brief Research Report

Published on 09 Jun 2025

[Scientist trust in medical research: a survey of authors from 28 countries](#)

Arch G. Mainous III, J. A. Kellie, Rachel E. Liu-Galvin, Barbara Durden

Valery M. Beau de Rochars

Gene Therapy – Nature

Volume 32 Issue 3, May 2025

<https://www.nature.com/gt/volumes/32/issues/3>

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 5 May 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/5>

Review article Open access

[**How do parents decide on genetic testing in pediatrics? A systematic review**](#)

Elena Sophia Doll, Seraina Petra Lerch, Katja Maria Schmalenberger, Karla Alex, ... Beate Ditzen

Article 101390

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 14 June 2025]

[No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 14 June 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 14 June 2025]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>
Special Section: Distress Migration and the Right to Health
[Reviewed earlier]

Health Economics, Policy and Law

Volume 20 - Issue 1 - January 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 4, May 2025

<https://academic.oup.com/heapol/issue/40/4>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 14 June 2025]
[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 11-12 / June 2025

<https://www.liebertpub.com/toc/hum/36/11-12>
Review

[Progress, Applications and Prospects of CRISPR-Based Genome Editing Technology in Gene Therapy for Cancer and Sickle Cell Disease](#)

Sha-sha Zang, Ruirui Zhang, Jia-run Zhang, Xi Zhang, and Jun Li

Pages:858–869

Published Online:12 May 2025

<https://doi.org/10.1089/hum.2024.262>

Humanitarian Practice Network

<https://odihpn.org/>
Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

May 13, 2025 Volume 58 Issue 5 p1033-1360

<https://www.cell.com/immunity/current>
[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 14 June 2025]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content/>

[Accessed 14 June 2025]

[No new digest content identified]

International Health

Volume 17, Issue 3, May 2025

<https://academic.oup.com/inthealth/issue/17/3>

[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024)

<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 5 (2025): May 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/124>

[Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 2, April 2025

<https://academic.oup.com/ije/issue/54/2>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18 Issue 1 2025

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1>

Table of contents

[Reviewed earlier]

JAMA

June 10, 2025, Vol 333, No. 22, Pages 1939-2030

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

[Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years - A Randomized Clinical Trial](#)

Amanda K. Rudman Spergel, MD; Iris Wu, PhD; Weiping Deng, PhD; et al.

JAMA. 2025;333(22):1977-1987. doi:10.1001/jama.2025.5646

This study examines the immunogenicity and safety of an investigational mRNA-based vaccine against seasonal influenza and SARS-CoV-2 in adults 50 years and older.

Special Communication

CONSORT 2025 Statement Updated Guideline for Reporting Randomized Trials

Sally Hopewell, DPhil; An-Wen Chan, MD, DPhil; Gary S. Collins, PhD; et al.

JAMA. 2025;333(22):1998-2005. doi:10.1001/jama.2025.4347

This Special Communication introduces the updated Consolidated Standards of Reporting Trials (CONSORT) 2025 statement, which includes substantive and structural changes to account for recent methodological advancements and feedback from end users.

Viewpoint

Unreliable Vaccine Information and the Erosion of Science

Jeremy W. Jacobs, MD, MHS; Garrett S. Booth, MD, MS

JAMA. 2025;333(22):1947-1948. doi:10.1001/jama.2025.5723

This Viewpoint explores how appointing vaccine skeptics to positions of power in the US government contributes to the spread of unreliable information, subverts public confidence in vaccines, and undermines the integrity of public health.

Testing the Boundaries of Presidential Powers in Health

Lawrence O. Gostin, JD; Stephen Vladeck, JD; Lauren E. Bateman, JD

JAMA. 2025;333(22):1949-1950. doi:10.1001/jama.2025.5122

This Viewpoint discusses the unprecedented assertion of presidential control over federal spending, including withholding of disbursements of appropriated funds for public health and foreign aid.

JAMA Health Forum

May 2025, Vol 6, No. 5

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

May 2025, Vol 179, No. 5, Pages 485-584

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

May 2025 - Volume 23 - Issue 5

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

May 2025 Volume 76 Issue 5 p749-960

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 82 (2025)
<https://www.jair.org/index.php/jair>
Contents
[Reviewed earlier]

Journal of Community Health

Volume 50, Issue 3 June 2025
<https://link.springer.com/journal/10900/volumes-and-issues/50-3>
[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
Vol. 8 No. 01 (2025)
<https://www.cmro.in/index.php/jcmro/issue/view/91>
[Reviewed earlier]

Journal of Development Economics

Volume 174 May 2025
<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/174/suppl/C>
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 1-2, February-April 2025
<http://journals.sagepub.com/toc/jre/current>
[Reviewed earlier]

Journal of Epidemiology & Community Health

May 2025 - Volume 79 - 5
<https://jech.bmj.com/content/79/5>
[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 2 June 2025
<https://onlinelibrary.wiley.com/toc/17565391/current>
[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 3 (2024)
<http://www.tandfonline.com/toc/rjge20/current>
Special Issue: 20th Anniversary Forum
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 2, May 2025

<https://muse.jhu.edu/issue/54734>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 3 June 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 2 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 4 pages: 1-1053 May 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

June 2025 - Volume 51 - 6

<http://jme.bmj.com/content/current>

[New issue; No digest content identified]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 1 (2025)

<https://institutionalrepository.aah.org/jpcrr/>

[New issue; No digest content identified]

The Journal of Pediatrics

Volume 282 July 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/282/suppl/C>

Research article Abstract only

[Evaluation of an Influenza Vaccination Program in the Pediatric Emergency Department](#)

Amethyst Alayari, Sonja I. Ziniel, Ethan Hawkins, Joan Mackenzie, Suchitra Rao

Article 114541

Research article Abstract only

[Effectiveness of Influenza Vaccination in Children Aged 6-59 Months during the Inaugural 2022-2023 Season in Andalusia, Spain](#)

Almudena Palma-García, David Moreno-Pérez, Mario Rivera-Izquierdo, Manuel Cardero-Rivas, ... Nicola Lorusso

Article 114558

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2025 - Volume 31 - Issue 4

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 2 June 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-2>

[Reviewed earlier]

Journal of the Royal Society – Interface

June 2025 Volume 22 Issue 227

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 4, May 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 99 • Number 4 • April 2025

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jun 14, 2025 Volume 405 Number 1049 5p2103-2178

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[**The uncertain future of migrant and refugee health**](#)

The Lancet

Comment

[**The Gavi Leap: radical transformation for a new global health architecture**](#)

Sania Nishtar

The Lancet Child & Adolescent Health

Jun 2025 Volume 9 Number 6 p361-438, e14

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

May 2025 Volume 7 Number 5

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jun 2025 Volume 13 Number 6 e974-e1150

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jun 2025 Volume 25 Number 6 p595-700, e316-e369

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jun 2025 Volume 10 Number 6 e433-e536

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jun 2025 Volume 13 Number 6 p473-568, e30-e32

<https://www.thelancet.com/journals/lanres/issue/current>

Articles

[**Efficacy, safety, and immunogenicity of the AS01_E-adjuvanted respiratory syncytial virus prefusion F protein vaccine \(RSVPreF3 OA\) in older adults over three respiratory syncytial virus seasons \(AReSVi-006\): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial**](#)

Michael G Ison, et al. on behalf of the AReSVi-006 study group

Maternal and Child Health Journal

Volume 29, Issue 5 May 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-5>

Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 5, July 2025

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 103, Issue 1 Pages: 1-241 March 2025
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

May 07, 2025 Volume 33 Issue 5 p1861-2310
<https://www.cell.com/molecular-therapy/current>

In this issue

Gene therapy has great potential for the treatment of genetic brain diseases. In particular, adeno-associated virus (AAV) gene therapy has been refined for three purposes: gene replacement, gene knockdown, and gene editing. This review covers the current state of gene therapies for inherited brain disorders, from basic research to clinical trials. AAV delivery, gene editing, and other topics are explored in the context of in vitro, in vivo, and clinical research on inherited brain diseases. Present limitations in the field and remaining questions are also discussed.

[Reviewed earlier]

Nature

Volume 642 Issue 8067, 12 June 2025
<https://www.nature.com/nature/volumes/641/issues/8067>
[New issue; No digest content identified]

Nature Biotechnology

Volume 43 Issue 5, May 2025
<https://www.nature.com/nbt/volumes/43/issues/5>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 14 June 2025)
[Reviewed earlier]

Nature Genetics

Volume 57 Issue 6, June 2025
<https://www.nature.com/ng/volumes/57/issues/6>
Comment 02 Jun 2025

Towards trustworthiness of precision medicine research for people with disabilities

People with disabilities are under-represented in general (non-disability-specific) precision medicine research (PMR), limiting access to its benefits. We examine key reasons for this, focusing on the role of (dis)trust, and identify areas for further inquiry to guide researchers and enhance PMR's trustworthiness for people with disabilities.

Alejandra Aguirre, Sandra Soo-Jin Lee, Maya Sabatello

Nature Human Behaviour

Volume 9 Issue 5, May 2025
<https://www.nature.com/nathumbehav/volumes/9/issues/5>
[Reviewed earlier]

Nature Medicine

Volume 31 Issue 5, May 2025

<https://www.nature.com/nm/volumes/31/issues/5>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 6, June 2025

<https://www.nature.com/nrd/volumes/24/issues/6>

[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 6, June 2025

<https://www.nature.com/nrg/volumes/26/issues/6>

[Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 6, June 2025

<https://www.nature.com/nri/volumes/25/issues/6>

World View 07 May 2025

[Reviewed earlier]

New England Journal of Medicine

Volume 392 No. 22 June 12, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 4 No. 5 May 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 14 June 2025]

[No new digest content identified]

Pediatrics

Volume 155, Issue 6 June 2025

<https://publications.aap.org/pediatrics/issue/155/5>

[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 6 June 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-6>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

[The fifth era of science: Artificial scientific intelligence](#)

Nina Miolane

Perspective | published 10 Jun 2025 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3003230>

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 14 June 2025)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 14 June 2025)

[Vaccine wastage rates and attributed factors in rural and urban areas in Uganda: Case of Mukono and Kalungu districts](#)

Mackline Ninsiima, Michael Muhoozi, Henry Luzze, Simon Kasasa

Research Article | published 10 Jun 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003745>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 14 June 2025)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 14 June 2025)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 14 June 2025]

[The impact of the COVID-19 pandemic on vaccinations in United States primary care practices](#)

Ömer Ataç, Lars E. Peterson, Teresa M. Waters

Research Article | published 10 Jun 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0325934>

Human Papillomavirus Vaccination uptake and associated factors among schools girls aged between 9–14 years in Ethiopia: Performance Monitoring for Action (PMA-ET) 2023, multilevel analysis

Ermias Bekele Enyew, Mulugeta Desalegn Kasaye, Shimels Derso Kebede, Mahider Shimelis Feyisa, Naol Gonfa Serbessa, Tsion Mulat Tebeje, Abiyu Abadi Tareke

Research Article | published 10 Jun 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0325557>

Fake news, misinformation, vaccine hesitancy and the role of community engagement in COVID-19 vaccine acceptance in Southern Ghana

Mawulom Kuatewo, Wisdom Ebelin, Phidelia Theresa Doegah, Matilda Aberese-Ako, Samuel Lissah, Atsu Godsway Kpordorlor, Lebene Kpodo, Senanu Djokoto, Evelyn Ansah

Research Article | published 10 Jun 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0316969>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 14 June 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

June 10, 2025 vol. 122 no. 23

<https://www.pnas.org/toc/pnas/122/23>

[New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 5, May 2025

<https://academic.oup.com/pnasnexus/issue/4/5>

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 2 - April 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 194 May 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/194/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

June 2025 Volume 292 Issue 2048

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 242 Pages 1-414 (May 2025)

<https://www.sciencedirect.com/journal/public-health/vol/242/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 1, April 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 1, January/February 2025

<https://journals.sagepub.com/toc/phrg/140/1>

[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 7, June 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 21 Issue 2, April 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 14 June 2025]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

10 Jun 2025

[Temporal trends in vaccine hesitancy among Caribbean health workers: analysis of 2021 and 2024 surveys](#)

Original research | English

Risk Analysis

Volume 45, Issue 5 Pages: 969-1185 May 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 14 June 2025]

[No new digest content identified]

Royal Society Open Science

June 2025 Volume 12 Issue 6

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

Science

Volume 388| Issue 6752| 12 Jun 2025

<https://www.science.org/toc/science/current>

Editorial

An American research crisis with real human consequences

BY Marc B. Parlange

12 Jun 2025: 1113

Strangling intellectual independence

BY Michael S. Harris

05 Jun 2025

... American higher education is now at risk—not because of any single rival, but because of two self-inflicted wounds. It's hard to imagine a more destructive one-two punch than what is happening today. One blow has been the federal government's ideologically driven cuts to research funding at universities. At center stage have been the nation's premier private institutions, with Harvard University bearing the brunt of attack at the moment. The other jab has been the ideologically driven attacks on academic freedom at state universities, as typified by recent legislation in Texas....

Science and Engineering Ethics

Volume 31, Issue 3 June 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-3>

[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 802| 11 Jun 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 14 June 2025]

[No new digest content identified]

Social Science & Medicine

Volume 371 April 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/371/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 14 June 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 3 June 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-3>

[New issue; No digest content identified]

Travel Medicine and Infectious Diseases

Volume 65 May–June 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/65/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 5 Pages: i-iv, 323-457 May 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 53 19 April 2025

<https://www.sciencedirect.com/journal/vaccine/vol/53/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 14 June 2025]

Open Access Article

Strengthening Vaccine Regulation: Insights from COVID-19 Vaccines, Best Practices, and Lessons for Future Public Health Emergencies

by Razieh Ostad Ali Dehaghi, Alireza Khadem Broojerdi, Alaa Magdy, Marie Valentin, Juliati Dahlan, Obaidullah Malik, Richard H. Siggers, Edwin Nkansah and Hiiti B. Sillo

Vaccines 2025, 13(6), 638; <https://doi.org/10.3390/vaccines13060638> - 12 Jun 2025

Abstract

Background: The COVID-19 pandemic necessitated immediate regulatory vaccine approvals to facilitate timely global access. The prevailing differences in economies and resources and the varying maturity of the regulatory systems worldwide resulted in different levels of capacity to ensure vaccine quality, safety, and [

Open Access Systematic Review

Safety and Immunogenicity of Co-Administration of Herpes Zoster Vaccines with Other Vaccines in Adults: A Systematic Review and Meta-Analysis

by Omid Reza Hosseini, Aysan Bazargan, Mads Frederik Eiberg, Alexander Printzlau Korsgaard, Raziye Niyati, Christina Ekenberg, Lars Nørregaard Nielsen and Zitta Barrella Harboe
Vaccines 2025, 13(6), 637; <https://doi.org/10.3390/vaccines13060637> - 12 Jun 2025

Abstract

Introduction: Herpes zoster (HZ), or shingles, is a vaccine-preventable disease with two approved vaccines: the live-attenuated vaccine (LZV) and the adjuvanted recombinant zoster vaccine (RZV). Evidence on the immunogenicity and adverse events (AEs) following co-administration with other vaccines in adults is limited. Thi

Open Access Systematic Review

Mapping Behavioral and Social Drivers of Influenza Vaccine Uptake in Older Adults: A Scoping Review

by Enming Zhang, Shuhui Shang, Yufei Xing, Jiasong Cui, Chen Pan, Holly Seale and Qiong Fang
Vaccines 2025, 13(6), 624; <https://doi.org/10.3390/vaccines13060624> - 10 Jun 2025

Abstract

Background/Objectives: Influenza vaccination plays a crucial role in reducing morbidity and mortality among older adults; however, uptake remains suboptimal, particularly in the post-COVID-19 pandemic. In many settings, countries have not recovered their influenza vaccine coverage rates to the same level as pre-COVID. Therefor

Value in Health

June 2025 Volume 28 Issue 6 p813-978

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 191 July 2025

<https://www.sciencedirect.com/journal/world-development/vol/191/suppl/C>

[Reviewed earlier]

.....

.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....

.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 14 June 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2506.09102 [pdf, html, other]

Revolutionizing Clinical Trials: A Manifesto for AI-Driven Transformation

Mihaela van der Schaar, Richard Peck, Eoin McKinney, Jim Weatherall, Stuart Bailey, Justine Rochon, Chris Anagnostopoulos, Pierre Marquet, Anthony Wood, Nicky Best, Harry Amad, Julianna Piskorz, Krzysztof Kacprzyk, Rafik Salama, Christina Gunther, Francesca Frau, Antoine Pugeat, Ramon Hernandez

This manifesto represents a collaborative vision forged by leaders in pharmaceuticals, consulting firms, clinical research, and AI. It outlines a roadmap for two AI technologies - causal inference and digital twins - to transform clinical trials, delivering faster, safer, and more personalized outcomes for patients. By focusing on actionable integration within existing regulatory frameworks, we propose a way forward to revolutionize clinical research and redefine the gold standard for clinical trials using AI. *[Excerpt]*

7 Conclusion: A Call to Action

This manifesto outlines a shared vision for leveraging AI to transform clinical trials into faster, more personalized, and more inclusive systems. By integrating causal inference and digital twins, we can accelerate the pace of discovery, expand the scope of questions answered, and deliver safer, more effective treatments to patients worldwide. Implementing AI in clinical trials requires a structured approach to ensure success and regulatory compliance. This includes pursuing robust validation, developing best practices for data sharing and standardization, ensuring methods are deployed in a complementary, rather than disruptive fashion, and increasing interdisciplinary education among all stakeholders involved with clinical trials. To scale adoption, pilot projects should target high-impact areas such as oncology or rare diseases. These projects can demonstrate the feasibility of AI-enhanced trials, providing a roadmap for broader implementation.

The path forward demands collaboration across academia, industry, and regulators. The stakes are high, but the potential rewards—a new era of patient-centered care—are even greater. This is our call to action: to embrace AI as a catalyst for change, redefining clinical trials for the benefit of patients everywhere. The future of medicine depends on it: as we move forward, let us always remember that our actions today will shape the patient care of tomorrow, making it more personalized, more inclusive, and ultimately, more successful.

arXiv:2506.06405 [pdf, other]

Impact of the WHO's 90-70-90 Strategy on HPV-Related Cervical Cancer Control: A Mathematical Model Evaluation in China

Hua Liu, Chunya Liu, Yumei Wei, Qibin Zhang, Jingyan Ma

In August 2020, the World Health Assembly approved the Global Strategy to eliminate cervical cancer, marking the first time that numerous countries committed to eliminating a form of cancer. China introduced the HPV vaccine in 2016 and has made significant advancements in both prevention and treatment strategies. However, due to the relatively late introduction of the vaccine, the burden of cervical cancer in China continues to rise. In light of this, we develop a compartmental model to assess the impact of the WHO's 90-70-90 strategy, along with adult catch-up vaccination, on the control of HPV-induced cervical cancer in China. We analyze the basic properties of the model and provide proofs of the local and global asymptotic stability of the equilibrium points. Additionally, a sensitivity analysis is performed, and we use the MCMC algorithm to fit the number of new cervical cancer cases and deaths in China from 1990 to 2021. The estimated basic reproduction number before and after the

introduction of the HPV vaccine in China is 1.5026 (95% CI: 1.4051-1.6002) and 1.0726 (95% CI: 0.9384-1.2067), respectively. The sensitivity analysis reveals that screening, as a non-pharmaceutical intervention, plays a crucial role in controlling the spread of the disease. We apply the 90-70-90 strategy to predict the future number of new cervical cancer cases and deaths in China. The results indicate that prioritizing the 70-90 target combination is the most cost-effective approach and can achieve the goal of zero new cervical cancer cases by 2061. Finally, an optimal control model is developed to explore the best implementation strategies for HPV vaccination and screening under various plausible scenarios.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 14 June 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 14 June 2025]

Cost-effectiveness of risk-stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

Tiago M. de Carvalho, Johannes Berkhof, Johannes A. Bogaards

medRxiv 2025.06.12.25329488; doi: <https://doi.org/10.1101/2025.06.12.25329488>

Measuring the growth of infectious disease modelling publications and their impact on policymaking: a Large Language Model-assisted bibliometric review

Paula Christen, Malik H A Ahmed, Brandon Chua Wen Bing, Panupong Chaowanasawat, Emma Chapman-Banks, Yusuf Ozkan, Sabine van Elsland, Anne Cori, Sarin Sarin, Matthew D Whitaker, Marc Chadeau-Hyam, Saudamini Vishwanath Dabak, Mark Jit

medRxiv 2025.06.12.25328864; doi: <https://doi.org/10.1101/2025.06.12.25328864>

Healthcare workers' beliefs, practices and experiences regarding the COVID-19 pandemic and resulting governance from preparedness and response plans in Faranah, Guinea

Carlos Rocha, Moussa Douno, Lena Landsmann, Kamis Diallo, Rebekah Wood, Mardjan Arvand, Carolin Meinus, Mamadou Diallo, Almudena Marí-Sáez

medRxiv 2025.06.10.25329321; doi: <https://doi.org/10.1101/2025.06.10.25329321>

A flexible agent-based modelling framework of multi-serotype pneumococcal carriage to evaluate vaccine strategies in large populations

Nefel Tellioglu, David Price, Xinghui Chen, Violeta Spirkoska, Yingying Wang, Robert Moss, Natalie Carvalho, Kylie Carville, Patricia T. Campbell, Jodie McVernon

medRxiv 2025.05.22.25327965; doi: <https://doi.org/10.1101/2025.05.22.25327965> *Revision*

Predictors of Delayed or Absent Measles, Mumps, and Rubella Vaccination in the US, 2018–2025

Nina B. Masters, Brianna M. Goodwin Cartwright, Patricia J. Rodriguez, Karen M. Gilbert, Duy Do, Nicholas L. Stucky

medRxiv 2025.06.09.25329274; doi: <https://doi.org/10.1101/2025.06.09.25329274>

Community adherence to the second dose of measles and rubella: a cross-sectional survey in a rural health district of Cameroon

Guy Stéphane Nloga, Adidja Amani, Florence Kissougle Nkongo, Roger Mathurin Mfoula Angoula, Fabrice Zobel Lekeumo Cheuyem
medRxiv 2025.06.07.25329191; doi: <https://doi.org/10.1101/2025.06.07.25329191>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 14 June 2025]

[No new digest content identified]

* * * *

Think Tanks

Brookings [to 14 June 2025]

<http://www.brookings.edu/>

Reports, Events

No new digest content identified.

Center for Global Development [to 14 June 2025]

<https://www.cgdev.org/>

All Research

CGD NOTE

USAID's Role in Global Health Supply Chain Programs and Implications of Aid Cuts: A Rapid Review

[Lyudmila Nepomnyashchiy et al.](#)

June 12, 2025

In early 2025, the Trump administration began making drastic cuts to USAID and other global health programming, including the reduction and/or elimination of long-standing global health supply chain programs. The United States has historically been a major funder of global health supply chains, and ...

Chatham House [to 14 June 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 14 June 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 14 June 2025]
[https://www.csis.org/Reports \[Selected\]](https://www.csis.org/Reports/[Selected])
No new digest content identified.

Kaiser Family Foundation [to 14 June 2025]
https://www.kff.org/search/?post_type=press-release
Newsroom
[Walgreens and KFF's Greater Than Campaign to Offer Free HIV/STD Testing in Stores on June 27](#)

June 12, 2025 News Release

DEERFIELD, Ill. & SAN FRANCISCO, June 12, 2025 – Walgreens and Greater Than HIV/STDs, a public information campaign from KFF, are joining with health departments and community organizations to provide free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for the nation's largest National...

McKinsey Global Institute [to 14 June 2025]
<https://www.mckinsey.com/mgi/overview>
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 14 June 2025]
<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified

Pew Research Center [to 14 June 2025]
<https://www.pewresearch.org/>
Latest Publications [Selected]
report Jun 11, 2025

[U.S. Image Declines in Many Nations Amid Low Confidence in Trump](#)

More than half of adults in 19 of 24 countries surveyed lack confidence in Trump's leadership on the world stage.

Rand [to 14 June 2025]
<https://www.rand.org/pubs.html>
Published Research [Selected]
Research Jun 12, 2025

[Automated Grading for Efficiently Evaluating the Dual-Use Biological Capabilities of Large Language Models](#)

The authors used an automated grader to evaluate the ability of large language models to answer knowledge-based questions and generate protocols that explain how to perform laboratory techniques that could be used to create biological threat proxies.

Commentary Jun 10, 2025

[We'll Be Arguing for Years Whether Large Language Models Can Make New Scientific Discoveries](#)

If AI can indeed make scientific discoveries, that would not only have practical impacts for society but would also provide evidence that we've achieved true digital intelligence. But reaching expert consensus on what counts as a scientific discovery by an AI may prove more elusive than expected.

Expert Insights Jun 9, 2025

Ten Practical Principles for Policy and Program Analysis

A good analysis should help the decisionmaker understand that a choice depends on key judgments rather than simply provide an answer. Most of the job of policy analysis is to figure out the right question to ask—or at least some good ones.

Urban Institute [to 14 June 2025]

<https://www.urban.org/publications>

New Research Publications - Selected

Brief

Reconciliation Bill Would Cut Marketplace Enrollment by over 5 Million People

June 13, 2025

Brief

House Reconciliation Bill Will Hit Lowest-Income Families the Hardest: A Summary of Preliminary Research Findings

June 13, 2025

World Economic Forum [to 14 June 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

Gender Gap Closes at Fastest Rate Since Pandemic – But Full Parity Still Over a Century Away

News 11 Jun 2025

:: The global gender gap has closed to 68.8%, led by economic and political advances – yet progress is still behind pre-pandemic pace, with full parity an estimated 123 years away.

:: Women outpace men in higher education but only 28.8 % reach senior leadership, a missed opportunity for greater economic resilience and growth amid global uncertainty.

:: Political empowerment sees strongest gains, yet with only 22.9% of the global gap closed to date it remains the biggest barrier to progress on parity worldwide.

:: Read the full report [here](#)

:::::
:::::

Public Consultations/Call for Inputs/Call for Papers

No new digest content identified

*

*

*

*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *